Company news

Cardiff Oncology, Inc. news in 2022

Cardiff Oncology, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Cardiff Oncology to Present at the Jefferies London Healthcare Conference

November 7, 2022

Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates

November 2, 2022

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates

September 11, 2022

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022

September 9, 2022

Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022

September 5, 2022

Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022

August 28, 2022

Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates

August 3, 2022

Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022

July 4, 2022

Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference

May 16, 2022

Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates

May 4, 2022

Cardiff Oncology Announces Departure of Chief Medical Officer

April 11, 2022

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

April 7, 2022

Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models

April 7, 2022

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC

March 21, 2022

Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting

March 7, 2022

Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference

February 28, 2022

Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights

February 23, 2022

Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference

January 19, 2022

Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

January 17, 2022

Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

January 10, 2022

Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

January 9, 2022

Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference

January 3, 2022

Decks in 2022